How often must GMP equipment and instruments be calibrated, and what must a calibration programme include?

1No regulation fixes the interval.

The US drug CGMP regulations require laboratory controls to include “the calibration of instruments, apparatus, gauges, and recording devices at suitable intervals in accordance with an established written program containing specific directions, schedules, limits for accuracy and precision, and provisions for remedial action in the event accuracy and/or precision limits are not met” (21 CFR 211.160(b)(4)).¹ Automatic, mechanical and electronic equipment used in manufacturing “shall be routinely calibrated, inspected, or checked according to a written program designed to assure proper performance”, with written records (211.68(a)).²

EU GMP Chapter 3 says measuring, weighing, recording and control equipment “should be calibrated and checked at defined intervals by appropriate methods”, with adequate records (3.41).³ ICH Q7, the GMP guide for active pharmaceutical ingredients, asks for critical equipment to be calibrated “according to written procedures and an established schedule” (5.30).⁴

None of these sets a number. The manufacturer sets and justifies the interval. FDA’s Q&A on equipment, answering a question about balances, says “the frequency of performance checks depends on the frequency of use of the scale and the criticality and tolerance of the process or analytical step”.⁵

2What a calibration programme must include.

ICH Q7 defines calibration as “the demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements”.⁴ The requirements for a programme to deliver that line up across the three texts.

Sources: 21 CFR 211.68, 211.160 and 211.194; EU GMP Chapters 3 and 6; ICH Q7 section 5.3.²¹⁶³⁷⁴

3Which equipment is in scope.

The scope follows the measurement, not the asset class. In US CGMP it covers laboratory instruments, apparatus, gauges and recording devices (211.160(b)(4)) and automatic, mechanical and electronic manufacturing equipment, including computers (211.68(a)).¹² EU GMP covers measuring, weighing, recording and control equipment (3.41).³ ICH Q7 covers control, weighing, measuring, monitoring and test equipment “that is critical for assuring the quality of intermediates or APIs” (5.30).⁴

Calibration is also built into qualification and validation. EU GMP Annex 15 lists calibration of instrumentation as part of installation qualification (3.9), expects process validation protocols to list the measuring, monitoring and recording equipment used “together with the calibration status” (5.22), and asks change control to consider the effect of a change on calibration (11.4).⁸

4Built-in checks and traceable standards.

FDA has answered whether a balance’s built-in auto-calibration can replace external checks. It cannot: “the auto-calibration feature of a balance may not be relied upon to the exclusion of an external performance check (21 CFR 211.68)”. External checks can be less frequent on a balance with an auto-calibrator. The auto-calibrator itself should be verified periodically, and FDA notes that “a common frequency is once a year”, using “National Institute of Standards and Technology (NIST)-traceable standards or NIST-accredited standards in use in other countries”.⁵

FDA adds that “all batches of a product manufactured between two successive verifications would be affected” should the check of the auto-calibrator reveal a problem.⁵ The longer the interval, the more work a failed check can reach.

5When an instrument fails calibration.

An instrument that does not meet its established specifications “shall not be used” (211.160(b)(4)), and Q7 says the same (5.34).¹⁴ Q7 adds that deviations from approved calibration standards on critical instruments “should be investigated to determine if these could have had an impact on the quality of the intermediate(s) or API(s) manufactured using this equipment since the last successful calibration” (5.35).⁴

Calibration status is also one of the first things checked when a result fails. FDA’s OOS guidance asks the analyst to use only instruments that meet established performance specifications and are properly calibrated, and lists poorly maintained or improperly calibrated equipment among the causes of frequent laboratory errors.⁹

6Using a contract calibration provider.

The EMA GMP data integrity Q&A says a company using a contract calibration service, on site or off site, should apply quality risk management to data criticality and risk, and assess the provider’s data governance systems when deciding on the contract. That assessment “may be achieved by on-site audit or desk-based assessment of information submitted by the service provider”.¹⁰

7How it runs in Seal.

In Seal’s calibration management, each calibration point keeps its as-found and as-left observations, recorder, procedure and reference standard, and the event links to the recorded uses of the instrument. Criticality, assessed from the process parameters, methods and release tests that depend on the instrument, drives calibration frequency, tolerances and overdue behaviour. An out-of-tolerance result opens an assessment of the work measured since the last acceptable calibration, and use permission stays a separate decision from a passing as-left check.

The equipment blueprint connects calibration, qualification, cleaning and maintenance evidence to the workflow that selects the asset, so a missing prerequisite stops the configured path. In the CMMS, the work order, parts, readings and return-to-service review share records with the equipment, laboratory and quality work they affect.